• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by AIxCrypto Holdings Inc.

    1/29/26 4:05:27 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIXC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.

    (Name of Issuer)


    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)


    74754R301

    (CUSIP Number)


    01/28/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74754R301


    1Names of Reporting Persons

    Alpha Capital Anstalt
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LIECHTENSTEIN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    36,003.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    36,003.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    36,003.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.51 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to 5, 7, 9 and 11: Based on 7,049,999 shares outstanding as of November 20, 2025 as reported on DEF-14A filed with the Securities and Exchange Commission on December 15, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    2042 Corte Del Nogal, Carlsbad, California 92011
    Item 2. 
    (a)Name of person filing:

    Alpha Capital Anstalt
    (b)Address or principal business office or, if none, residence:

    Altenbach 8, FL-9490 Vaduz, Liechtenstein
    (c)Citizenship:

    Liechtenstein
    (d)Title of class of securities:

    COMMON STOCK, $0.001 PAR VALUE PER SHARE
    (e)CUSIP No.:

    74754R301
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    36,003.00
    (b)Percent of class:

    0.51%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    36,003.00

     (ii) Shared power to vote or to direct the vote:

    0 Shares

     (iii) Sole power to dispose or to direct the disposition of:

    36,003.00

     (iv) Shared power to dispose or to direct the disposition of:

    0 Shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Alpha Capital Anstalt
     
    Signature:/s/ Konrad Ackermann
    Name/Title:Konrad Ackermann/Director
    Date:01/29/2026
    Get the next $AIXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: $10 million FFAI Strategic Investment, 1M+ Wallets, and Sei Collaboration

    LOS ANGELES, Feb. 2, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ: AIXC, "AIxC" or the "Company"), an advanced interactive platform bridging Web2 to Web3 with Embodied AI (EAI) and Real World Asset (RWA), today shared a weekly business update from Jerry Wang, Co-CEO of AIxC. "FF has signed a stock purchase agreement with a designated third party identified by AIxC." AIXC will fund FF $10 million, before offering expenses, and FF will issue the third party with $10 million in FF Class A common stock based on the most recent closing price prior to the closing date. Closing is expected to occur on or shortly after February 13, 2026, subject to customary closing conditions and stockholder approv

    2/2/26 11:21:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxC and Sei Development Foundation Announce Strategic Collaboration

    LOS ANGELES, Feb. 2, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or the ", Company", )), a U.S.-Nasdaq listed company dedicated to building a world-leading ecosystem that integrates AI and blockchain while bridging Web2 and Web3, and the Sei Development Foundation today announced a strategic technology collaboration to explore opportunities in high-performance blockchain infrastructure. Sei Development Foundation is an independent US non-profit dedicated to the advancement and adoption of open source, permissionless protocols like Sei Network – the fastest EVM Layer-1 blockchain built to support world-scale decentralized applications.

    2/2/26 11:21:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Inc. Surpasses 1.1 Million Registered Wallets as AIxC Hub Launches "Tenki" Interactive Game

    LOS ANGELES, Jan. 28, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or the ", Company", )), an advanced interactive platform bridging Web2 to Web3 with Embodied AI (EAI) and Real World Asset (RWA), today announced that total registered wallets on AIxC Hub have exceeded 1.1 million, coinciding with the launch of Tenki, a new AI-powered interactive game now available within the platform's Playground section. Tenki: AI Agent–Driven Interactive Entertainment Tenki is an AI agent–driven interactive game designed for entertainment, inspired by culturally rooted metaphy

    1/28/26 3:01:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    SEC Filings

    View All

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/2/26 5:03:24 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AIxCrypto Holdings Inc.

    SCHEDULE 13G/A - AIxCrypto Holdings, Inc. (0001460702) (Subject)

    1/29/26 4:05:27 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    1/6/26 1:32:44 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials